Transgene Crescita futura

Future criteri di controllo 0/6

Si prevede che gli utili di Transgene diminuiranno del 34.8% all'anno, mentre si prevede che il fatturato annuo crescerà del 2.9% all'anno. Si prevede che l'EPS diminuirà del 35% all'anno.

Informazioni chiave

-34.8%

Tasso di crescita degli utili

-35.0%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	42.4%
Tasso di crescita dei ricavi	2.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	14 Oct 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:TGNA - Stime future degli analisti e dati finanziari passati (EUR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	12	-56	-62	-61	1
12/31/2025	17	-47	-54	-52	1
12/31/2024	22	-30	-40	-38	1
6/30/2024	6	-23	-39	-36	N/A
3/31/2024	7	-23	-38	-35	N/A
12/31/2023	8	-22	-37	-35	N/A
9/30/2023	8	-28	-36	-34	N/A
6/30/2023	9	-33	-35	-33	N/A
3/31/2023	10	-33	-28	-26	N/A
12/31/2022	10	-33	-22	-20	N/A
9/30/2022	14	-28	-18	-17	N/A
6/30/2022	18	-23	-15	-15	N/A
3/31/2022	18	-21	-21	-20	N/A
12/31/2021	17	-20	-27	-26	N/A
9/30/2021	13	-23	-29	-28	N/A
6/30/2021	9	-27	-31	-30	N/A
3/31/2021	9	-22	-30	-29	N/A
12/31/2020	10	-17	-30	-29	N/A
9/30/2020	12	-11	-31	-30	N/A
6/30/2020	14	-6	-33	-31	N/A
3/31/2020	14	-12	-28	-27	N/A
12/31/2019	13	-19	-24	-22	N/A
9/30/2019	11	-6	-24	-23	N/A
6/30/2019	8	8	-23	-23	N/A
3/31/2019	8	8	-26	-25	N/A
12/31/2018	7	8	-29	-28	N/A
9/30/2018	7	-10	-31	-29	N/A
6/30/2018	7	-29	-32	-30	N/A
3/31/2018	7	-31	N/A	-33	N/A
12/31/2017	7	-32	N/A	-35	N/A
9/30/2017	8	-32	N/A	-36	N/A
6/30/2017	9	-31	N/A	-37	N/A
3/31/2017	9	-28	N/A	-35	N/A
12/31/2016	10	-24	N/A	-34	N/A
9/30/2016	10	-26	N/A	-37	N/A
6/30/2016	9	-28	N/A	-40	N/A
3/31/2016	9	-33	N/A	-43	N/A
12/31/2015	10	-38	N/A	-45	N/A
9/30/2015	10	-40	N/A	-48	N/A
6/30/2015	10	-42	N/A	-50	N/A
3/31/2015	11	-41	N/A	-52	N/A
12/31/2014	11	-41	N/A	-54	N/A
9/30/2014	13	-41	N/A	-52	N/A
6/30/2014	15	-41	N/A	-50	N/A
3/31/2014	15	-42	N/A	-50	N/A
12/31/2013	16	-43	N/A	-50	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che TGNA rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che TGNA rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che TGNA rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di TGNA ( 2.9% all'anno) crescerà più lentamente rispetto al mercato German ( 5.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di TGNA ( 2.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di TGNA è previsto essere elevato tra 3 anni

Transgene Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

First half 2024 earnings released: €0.16 loss per share (vs €0.16 loss in 1H 2023)

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

New minor risk - Shareholder dilution

Less than half of directors are independent

New major risk - Financial position

Full year 2023 earnings released: €0.22 loss per share (vs €0.33 loss in FY 2022)

Transgene SA Announces Chief Financial Officer Changes

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

New major risk - Financial position

New minor risk - Share price stability

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Full year 2022 earnings released: €0.33 loss per share (vs €0.21 loss in FY 2021)

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

No longer forecast to breakeven

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

First half 2022 earnings released

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

No longer forecast to breakeven

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

No longer forecast to breakeven

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

First half 2021 earnings released

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019)

Revenue misses expectations

New 90-day high: €2.84

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

New 90-day high: €2.69

New 90-day high: €2.60

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

New 90-day high: €1.74

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

First half 2020 earnings released: €0.03 loss per share

New 90-day high: €1.57

Transgene SA Announces the Presentation of the Detailed Results from the Phase 1b/2 Trial Combining TG4001, a HPV16-Targeted Therapeutic Vaccine, with Avelumab (BAVENCIO®)

Transgene Announces Detailed Results from the Phase 1B/2 Trial Combining TG4001

Transgene Announces Detailed Results of the Data from the Phase 1b/2 Trial Combining TG4001

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

Transgene SA to Report Fiscal Year 2009 Results on 03/22/2010

First half earnings released

New 90-day low - €1.33

A Chinese Investment Fund acquired an unknown minority stake in Shanghai Tasly Pharmaceutical Co., Ltd from Transgene SA (ENXTPA:TNG) for $22.2 million.

Vaxxel SAS acquired DuckCelt®-T17 cell line of Transgene SA (ENXTPA:TNG).

Mediolanum Farmaceutici S.P.A. acquired ElsaLys Biotech SA.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita